Related Experiment Video
Updated: Dec 11, 2025
Synthesis of Soft Polysiloxane-urea Elastomers for Intraocular Lens Application
Published on: March 8, 2019
Single subconjunctival injection formulation using sol-gel mesoporous silica as a controlled release system for
Yaoyao Sun1, Kristyn Huffman, William R Freeman
1From the Department of Ophthalmology, Jacobs Retina Center at Shiley Eye Institute, University of California San Diego, La Jolla, California, USA. Y. Sun is now at the Department of Ophthalmology, Ophthalmology & Optometry Center, Peking University People's Hospital, Beijing, China.
Purpose:
To develop a mesoporous silica drug delivery system and target drop-free care after cataract surgery with a single subconjunctival injection.
Setting:
Laboratory.
Design:
Experimental animal study.
Methods:
Ketorolac was infiltration-loaded into sol-gel mesoporous silica particles encapsulated with poly(allylamine hydrochloride) and poly(sodium 4-styrenesulfonate) using a layer-by-layer adsorption technique (SG-Ket-LBL). The formulation was subjected to an in vitro and in vivo drug release study in addition to ocular toxicology evaluation.
Results:
Thermogravimetric analysis revealed that the drug loading efficiency was 4.4% for the SG-Ket-LBL particles. The in vivo safety study demonstrated that the formulation was well tolerated after subconjunctival injection and aqueous humor pharmacokinetics showed sustained therapeutic drug release for the targeted time window of 6 to 8 weeks.
Conclusions:
Findings indicated that sol-gel mesoporous silica could be used as a drug carrier for subconjunctival administration. The tested formulation, SG-Ket-LBL, provided therapeutic ketorolac for 6 to 8 weeks, which might be used for a single subconjunctival injection to replace nonsteroidal anti-inflammatory drug eyedrops after cataract surgery.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment